BioSpace News Archive

Invectys, Inc. and CTMC today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for a Phase 1/2a clinical study of IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors.

Insilico Medicine (“Insilico”), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated ISM4312A as a preclinical candidate targeting DGKA with an AI-identified target and AI-designed structure for immuno-oncology therapeutics.

NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), today announced that the U.S. FDA has granted Orphan Drug Designation to NS-018 (ilginatinib), an investigational treatment for myelofibrosis (MF), a rare and incurable blood cancer.

Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, was selected by CSL Behring https://www.gilead.com/ as a limited distribution partner for HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy option for hemophilia B.

Magenta Therapeutics (Nasdaq: MGTA) today announces that, per the clinical trial protocol for the MGTA-117 Phase 1/2 Dose Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), it has stopped dosing participants at the Cohort 4 dosing level (0.13 mg/kg) and plans to dose additional participants at the Cohort 3 dosing level (0.08 mg/kg).

Capio, one of the largest healthcare asset management companies in the country, announced nine internal leadership promotions, including the establishment of three new executive positions.

BiondVax Pharmaceuticals Ltd. announced the closing of its underwritten public offering with gross proceeds to the Company to be $8,000,000, before deducting underwriting discounts and other expenses payable by the Company.

Vancouver, British Columbia--(Newsfile Corp. - December 20, 2022) - CVR Medical Corp. (TSXV: CVM.H) (OTC: CRRVF) (“CVR Medical” or the “Company” or “we”) a Canadian listed and US based healthcare company in the medical device market is pleased to announce an agreement with CVR Global Inc.

The global mRNA therapeutics market size was exhibited at USD 48.1 billion in 2022 and it is expected to hold around USD 128.14 billion by 2030, growing at a CAGR of 13.03% from 2022 to 2030.

CVRx, Inc. announced that Kevin Hykes will join its Board of Directors effective December 21, 2022.